Mast cell‐pain connection in eosinophilic esophagitis
Authors: Simin Zhang, Tetsuo Shoda, Seema S. Aceves, Nicoleta C. Arva, Mirna Chehade, Margaret H. Collins, Evan S. Dellon, Gary W. Falk, Nirmala Gonsalves, Sandeep K. Gupta, Ikuo Hirano, Paneez Khoury, John Leung, Amanda K. Rudman Spergel, Jonathan M. Spergel, Joshua B. Wechsler, Guang‐Yu Yang, Glenn T. Furuta, Marc E. Rothenberg
Journal: Allergy (2022)

M.E.R. is a consultant for Pulm One, Spoon Guru, Allakos, ClostraBio, Serpin Pharm, Celgene, Shire, AstraZeneca, GlaxoSmithKline, Allakos, Adare, Regeneron, and Novartis and has an equity interest in the first five, as well as royalties from reslizumab (Teva Pharmaceuticals) and UpToDate. M.E.R. is an inventor of patents owned by Cincinnati Children's Hospital Medical Center. T.S. has funding from the NIH and is a co-inventor of patents owned by Cincinnati Children's Hospital Medical Center. M.H.C. is a consultant for Alimentiv (formerly Robarts Clinical Trials, Inc), Allakos, Arena, AstraZeneca, Calypso, Esocap, GlaxoSmithKline, Receptos/Celgene/BMC, Regeneron, and Takeda and received research funds from Receptos/Celgene/BMC, Regeneron, and Takeda. J.B.W. is a consultant for Allakos, Regeneron, Sanofi/Genzyme, AstraZeneca, and InveniAI and received clinical trial support from Allakos and Regeneron. S.K.G. is a consultant for Abbott, Adare, Allakos, Celgene, Gossamer Bio, QOL, UpToDate, Medscape, and Viaskin and received research support from Shire, Allakos, Adare, and CEGIR (NIH U54 AI117804). J.M.S. has funding from the NIH, Regeneron, Sanofi, Novartis, and FARE; is a consultant for Regeneron, Allakos, Sanofi, Novartis, and Takeda; and is an author for UpToDate. S.A.A. has funding from NIH and is an educational speaker for MedScape and Sanofi-Regeneron, a consultant for AstraZeneca, and an author for UpToDate. M.C. received consulting fees from Regeneron, Allakos, Adare/Ellodi, Shire/Takeda, AstraZeneca, Sanofi, and Bristol Myers Squibb and received research funding from Regeneron, Allakos, Shire/Takeda, AstraZeneca, Adare/Ellodi, and Danone. E.S.D. received research funding from Adare/Ellodi, Allakos, Arena, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, and Shire/Takeda; received consulting fees from Abbott, Abbvie, Adare/ Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Landos, Morphic, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, and Shire/Takeda; and received educational grants from Allakos, Banner, and Holoclara. A.K.R.S.'s co-authorship of this publication does not necessarily constitute endorsement by the National Institute of Allergy and Infectious Diseases, the National Institutes of Health or any other agency of the United States government. S.Z. has no relevant conflicts of interest. I.H. received research funding from Adare/Ellodi, Allakos, Arena, AstraZeneca, Meritage, Celgene/Receptos/BMS, Regeneron/Sanofi, and Shire/Takeda; received consulting fees from Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Celgene/Receptos/BMS, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calyx, Phathom, Regeneron, Sanofi, and Shire/Takeda; and is an educational speaker for MedScape and Sanofi-Regeneron. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.